Portfolio company
Grannus Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Grannus Therapeutics develops selective Hsp90 protein inhibitors for patients with ovarian cancer and other solid tumours.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
ProteoValent Therapeutics
This company develops targeted protein degrader therapies for cancer and haematology patients.
THERAtRAME
The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.
Biotheryx
The company develops protein degrader medicines for patients with cancer and inflammatory diseases.
Apim Therapeutics
This clinical-stage biotechnology company develops peptide drugs targeting cellular stress responses for patients with advanced cancers including ovarian cancer and sarcoma.
Glionova AB
Glionova AB develops orally available oncolytic small molecules to treat glioblastoma and other aggressive cancers for patients with high unmet medical needs.
GQ Targeting
This biotechnology company develops small molecule drugs targeting G-quadruplex structures to treat patients with solid tumours.
Type6 Therapeutics
This deep-tech company develops kinase inhibitors for cancer treatment, intercepting enzymes in their inactive states to address drug resistance for patients with aggressive tumours.
Incyclix Bio
This biotechnology firm develops cyclin-dependent kinase 2 inhibitors to treat patients with advanced or resistant cancers, including breast and ovarian malignancies.